TheranosticTrials.org

Clinical Trial · NCT07537010

3D1015 Injection for Patients With mCRPC

Overview

This open-label clinical study investigates 3D1015 Injection (Lu 177-PSMA-3D1015) in adult males with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Participants will receive intravenous infusions of 3D1015, with treatment regimens dynamically individualized to optimize patient safety and outcomes. The primary objectives are to assess the safety, tolerability, and dosimetry of the injection. Secondary objectives include evaluating preliminary anti-tumor efficacy and exploring the optimal dosing regimen.

Sponsor

Affiliated Hospital of Jiangnan University

Phase

Phase 1

Contacts

chunjing Yu (CONTACT)

ycjwxd1978@jiangnan.edu.cn

15312238622

ClinicalTrials.gov

NCT07537010

Drug / Compound

PSMA-3D1015

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Presence of at least one metastatic lesion at baseline.
  • Histologically or cytologically confirmed prostate adenocarcinoma.
  • Confirmed progressive metastatic castration-resistant prostate cancer (mCRPC) that is refractory to or has progressed following prior treatments.

Exclusion

  • A superscan as seen in the baseline bone scan.
  • Receipt of other systemic anti-cancer therapies within 4 weeks prior to study entry.